Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa G Lechner

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|August 1, 2024
A pathologically expanded, clonal lineage of IL-21-producing CD4+ T cells drives inflammatory neuropathyMaryamsadat Seyedsadr, Madison F Bang, Ethan C McCarthy, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapyMelissa G Lechner, Saman S Karimi, Keegan Barry-Holson, et al.
Urology|February 5, 2013
Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1Sarah M Russell, Melissa G Lechner, Anusuya Mokashi, et al.
Clinical Breast Cancer|January 14, 2022
Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort StudyNikhita Kathuria-Prakash, Lauren Antrim, Nicholas Hornstein, et al.
Oral Oncology|July 2, 2011
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristicsSarah M Russell, Melissa G Lechner, Lucy Gong, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
UTX Epigenetically Imposes a Cytolytic Effector Program in Autoreactive Stem-like CD8+ T cell ProgenitorsHo-Chung Chen, Hsing Hui Wang, Lisa A Kohn, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Polyfunctional IL-21<sup>+</sup> IFNG<sup>+</sup> T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapyNicole Huang, Jessica Ortega, Kyleigh Kimbrell, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 29, 2023
Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid CancerMax A Schumm, Michelle L Shu, Elena G Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasKatherine A Murphy, Melissa G Lechner, Flavia E Popescu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor EfficacyMelissa G Lechner, Mandy I Cheng, Anushi Y Patel, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|August 1, 2024
A pathologically expanded, clonal lineage of IL-21-producing CD4+ T cells drives inflammatory neuropathyMaryamsadat Seyedsadr, Madison F Bang, Ethan C McCarthy, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapyMelissa G Lechner, Saman S Karimi, Keegan Barry-Holson, et al.
Urology|February 5, 2013
Establishment and characterization of a new human extragonadal germ cell line, SEM-1, and its comparison with TCam-2 and JKT-1Sarah M Russell, Melissa G Lechner, Anusuya Mokashi, et al.
Clinical Breast Cancer|January 14, 2022
Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort StudyNikhita Kathuria-Prakash, Lauren Antrim, Nicholas Hornstein, et al.
Oral Oncology|July 2, 2011
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristicsSarah M Russell, Melissa G Lechner, Lucy Gong, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
UTX Epigenetically Imposes a Cytolytic Effector Program in Autoreactive Stem-like CD8+ T cell ProgenitorsHo-Chung Chen, Hsing Hui Wang, Lisa A Kohn, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Polyfunctional IL-21<sup>+</sup> IFNG<sup>+</sup> T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapyNicole Huang, Jessica Ortega, Kyleigh Kimbrell, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 29, 2023
Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid CancerMax A Schumm, Michelle L Shu, Elena G Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasKatherine A Murphy, Melissa G Lechner, Flavia E Popescu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor EfficacyMelissa G Lechner, Mandy I Cheng, Anushi Y Patel, et al.
Pageof 6